Gene Variations Linked to Ethnicity May Hint at Response to Schizophrenia Drugs | GenomeWeb
Variations in the regulator of G protein signaling 4 (RGS4) may help predict how well patients of different ethnicities respond to certain schizophrenia medications — a noteworthy discovery because treatments for the disorder have notoriously varying efficacy and adverse-event profiles that greatly affect compliance.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.